

UCB S.A.

ISIN: BE0003739530

WKN: 992418

Asset Class: Stock

Company

2024/09/18 17:18:33



Price

159.60

EUR

Difference

0.47%(0.75)

160.00

140.00

120.00

100.00

80.00

60.00

2023 2023 2024 2024 2024 2024



Contact Details

UCB SA

Tel: +32-2-559-99-99

--

Fax: +

Allée de la Recherche, 60

Web: <http://www.ucb.com>

1070 Brüssel

E-mail: contactucb@ucb.com

Company Profile

UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	3,444,000,000		3,304,000,000		3,710,000,000	
Common stock capital		584,000,000		584,000,000		584,000,000
Fixed assets	12,095,000,000		12,564,000,000		10,500,000,000	
Equity capital of a company		8,975,000,000		9,064,000,000		8,386,000,000
Cash and cash equivalents	861,000,000		899,000,000		1,263,000,000	
Accrued liabilities		439,000,000		333,000,000		503,000,000
Other assets	-		-		-	
Current liabilities		2,616,000,000		3,112,000,000		2,824,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		3,948,000,000		3,692,000,000		3,000,000,000
Different income		-		-		-
Other liabilities		227,000,000		344,000,000		238,000,000
Total assets	15,539,000,000	15,539,000,000	15,868,000,000	15,868,000,000	14,210,000,000	14,210,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	9,083	8,703	8,561
Equity ratio	57.76%	57.12%	59.01%
Debt-equity ratio	73.14%	75.07%	69.45%

Others

	2023	2022	2021
Tax Expense Rate	22.22%	17.81%	13.87%

Income statement

	2023	2022	2021
Turnover	5,252,000,000	5,517,000,000	5,777,000,000
Net income	343,000,000	420,000,000	1,056,000,000
EBIT	558,000,000	578,000,000	1,269,000,000
Operating income before taxes	441,000,000	511,000,000	1,226,000,000
Cash Flow	617,000,000	1,045,000,000	1,490,000,000
Net interest income	-117,000,000	-67,000,000	-43,000,000
Research and development expenses	1,630,000,000	1,670,000,000	1,629,000,000
Income taxes	98,000,000	91,000,000	170,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	578,223	633,919	674,804

Board of Directors

Jonathan Peacock	Chairman of Supervisory Board
Dame Davies	Member of Supervisory Board
Dolca Thomas	Member of Supervisory Board
Jan Berger	Member of Supervisory Board
Susan Gasser	Member of Supervisory Board
Charles-Antoine Janssen	Member of Supervisory Board
Cyril Janssen	Member of Supervisory Board
Jonkheer Cédric van Rijckevorsel	Member of Supervisory Board
Maëlys Castella	Member of Supervisory Board
Nefertiti Greene	Member of Supervisory Board
Pierre Gurdjian	Member of Supervisory Board
Rodolfo Savitzky	Member of Supervisory Board
Ulf Arne Wiinberg	Member of Supervisory Board

Members of Management Board

Jean-Christophe Tellier	Chairman of Managing Board
Alistair Henry	Member of Executive Committee
Denelle Waynick Johnson	Member of Executive Committee
Emmanuel Caeymaex	Member of Executive Committee
Fiona du Monceau	Member of Executive Committee
Iris Löw-Friedrich	Member of Executive Committee
Jean Luc Fleurial	Member of Executive Committee
Kirsten Lund-Jurgensen	Member of Executive Committee
Sandrine Dufour	Member of Executive Committee